Page 279 - Drug Class Review

Drug Effectiveness Review Project

placebo
18.2
72.7
53

Alzheimer classification: Mild-moderate
29.2 Primary Outcome Measures: CIBI; ADAS-Cog; FCCA Secondary Outcome Measures: ADAS-Noncog; ADAS-Total score; MMSE; GDS Timing of assessments: Baseline and every 6 weeks At week 30 significantly more patients in the placebo group were placed in a nursing home or had died than in the TAC 160 mg/d group (7% vs. 4%; OR 2.8; 95% CI: 1.0 – 7.8; P = 0.046); no significant differences between placebo and TAC 80 mg/d group (7% vs. 7%) Significant differences in favor of 160 mg/d TAC vs. placebo for CIBI (P = 0.002) and ADAS- A subgroup analysis revealed t
Groups similar at baseline: Yes
40- 80; 40-60-120; 40-80-120- Health Outcome Measures: Cog (P < 0.001)
tacrine 160 mg/d 73; 73; 72.8 48; 55; 51 17.1; 18.7; 18.8 30.9; 28.5; 28 Intermediate Outcome Measures: APOE-[epsilon]2-3 genotype

• • • • •

Final Report Update 1 Authors: Knapp et al. Year: 1994 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Ethnicity: NR Other germane population qualities: MMSE • ADAS-Cog • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs